Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name MVF-HER-2(597-626)/MVF-HER-2(266-296) Vaccine
Synonyms
Therapy Description

MVF-HER-2(597-626)/MVF-HER-2(266-296) Vaccine is a combination of two chimeric peptide vaccines comprising a promiscuous measles virus (MVF) T cell epitope fused to Erbb2 (Her2) peptides spanning amino acids 597-626 and 266-296, which potentially inhibits Erbb2 (Her2) signaling and induces antibody-dependent cellular cytotoxicity against Erbb2 (Her2)-expressing tumors (PMID: 30804020).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MVF-HER-2(597-626)/MVF-HER-2(266-296) Vaccine HER2 (ERBB2) Vaccine 14 MVF-HER-2(597-626)/MVF-HER-2(266-296) Vaccine is a combination of two chimeric peptide vaccines comprising a promiscuous measles virus (MVF) T cell epitope fused to Erbb2 (Her2) peptides spanning amino acids 597-626 and 266-296, which potentially inhibits Erbb2 (Her2) signaling and induces antibody-dependent cellular cytotoxicity against Erbb2 (Her2)-expressing tumors (PMID: 30804020).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06414733 Phase I MVF-HER-2(597-626)/MVF-HER-2(266-296) Vaccine Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Not yet recruiting USA 0


Additional content available in CKB BOOST